Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR) Stock Price, Analysis & Data
| Bid | 16.64 |
| Market Cap | 1.21B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 627.78M |
| Beta | n/a |
| EPS (ttm) | 171.01 |
| PE Ratio (ttm) | 0.13 |
| Forward PE | -5.84 |
| P/B (ttm) | -8.05 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 28.05 |
| Volume | 971,578 |
| Avg. Volume (20D) | 1,173,037 |
| Open | 23.48 |
| Previous Close | 23.59 |
| Day's Range | 21.80 - 23.51 |
| 52-Week Range | 6.50 - 50.20 |
| Analyst | n/a |
| Price Target | 40 (79.05%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VOR
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, ...
Financial Performance
In 2025, Vor Biopharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -695.98M, an increase of 495.29%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for VOR stock is "null". The 12-month stock price forecast is 40, which is upside of 79.05% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
